bevacizumab + liposomal doxorubicin + temsirolimus

This is an investigational combination therapy consisting of three agents: - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. - **Liposomal doxorubicin** is a formulation of the anthracycline chemotherapeutic doxorubicin encapsulated in liposomes, which enhances delivery to tumors and reduces cardiotoxicity. - **Temsirolimus** is an mTOR inhibitor that blocks the mammalian target of rapamycin (mTOR) pathway, leading to inhibition of cell proliferation and angiogenesis. The rationale for this combination arises from their complementary mechanisms. Bevacizumab and liposomal doxorubicin are both active in gynecologic and breast malignancies but share resistance mechanisms involving upregulation of hypoxia-inducible factor 1-alpha (HIF-1α). Temsirolimus inhibits HIF-1α by blocking mTOR signaling, potentially overcoming resistance. This regimen has been studied primarily in phase I clinical trials for advanced or recurrent gynecologic cancers and breast cancer, showing manageable toxicity profiles and preliminary evidence of anti-tumor activity[1][2][3].

Brand names

DoxilAvastinTorisel

Other names

DAT